Spyre Therapeutics (SYRE) announced Spyre has been added to the Nasdaq Biotechnology Index effective prior to market open, Monday, December 23.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- TD says Spyre has ‘superior TL1A program’ after Teva data
- Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG
- Spyre Therapeutics initiated with a Hold at JonesResearch
- Spyre Therapeutics announces first participants dosed in Phase 1 trial
- Spyre Therapeutics 7.275M share Spot Secondary priced at $27.50